PetIQ Inc (NASDAQ:PETQ) was the target of unusually large options trading activity on Tuesday. Investors purchased 1,840 call options on the company. This represents an increase of 2,731% compared to the typical daily volume of 65 call options.

In other news, insider Will Santana sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 22nd. The shares were sold at an average price of $37.58, for a total transaction of $751,600.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Ecp Helios Partners Iv, L.P. sold 1,838,836 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $37.15, for a total transaction of $68,312,757.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,023,503 shares of company stock worth $112,721,308. Insiders own 45.26% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Harvest Fund Management Co. Ltd purchased a new stake in shares of PetIQ during the 3rd quarter worth $135,000. Zions Bancorporation purchased a new stake in shares of PetIQ during the 3rd quarter worth $187,000. Advisory Services Network LLC boosted its position in shares of PetIQ by 296.0% during the 3rd quarter. Advisory Services Network LLC now owns 4,950 shares of the company’s stock worth $195,000 after purchasing an additional 3,700 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in shares of PetIQ during the 3rd quarter worth $200,000. Finally, Cim LLC purchased a new stake in shares of PetIQ during the 3rd quarter worth $204,000.

A number of equities analysts recently weighed in on the stock. Oppenheimer lifted their price objective on shares of PetIQ from $28.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, October 5th. Jefferies Financial Group reiterated a “buy” rating on shares of PetIQ in a research report on Friday, August 24th. Raymond James reiterated a “buy” rating and issued a $45.00 price objective (up from $33.00) on shares of PetIQ in a research report on Wednesday, September 19th. CL King assumed coverage on shares of PetIQ in a research report on Friday, September 28th. They issued a “buy” rating and a $49.00 price objective on the stock. Finally, SunTrust Banks lifted their price objective on shares of PetIQ to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 15th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $40.67.

NASDAQ:PETQ opened at $31.27 on Wednesday. PetIQ has a 1-year low of $17.50 and a 1-year high of $43.93. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.90 and a current ratio of 2.00. The firm has a market capitalization of $848.80 million, a P/E ratio of 80.18, a PEG ratio of 1.74 and a beta of 1.58.

PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Tuesday, November 13th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.21. PetIQ had a negative net margin of 0.76% and a positive return on equity of 11.40%. The firm had revenue of $131.40 million for the quarter, compared to analyst estimates of $125.22 million. During the same period last year, the firm posted $0.30 EPS. PetIQ’s quarterly revenue was up 116.8% on a year-over-year basis. Analysts forecast that PetIQ will post 0.76 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Investors Buy High Volume of Call Options on PetIQ (PETQ)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/11/14/investors-buy-high-volume-of-call-options-on-petiq-petq.html.

PetIQ Company Profile

PetIQ, Inc operates as a pet health and wellness company. It provides veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.

Featured Article: What do investors mean by earnings per share?

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.